175 related articles for article (PubMed ID: 30108156)
41. TP53 gene mutations in Hodgkin lymphoma are infrequent and not associated with absence of Epstein-Barr virus.
Maggio EM; Stekelenburg E; Van den Berg A; Poppema S
Int J Cancer; 2001 Oct; 94(1):60-6. PubMed ID: 11668479
[TBL] [Abstract][Full Text] [Related]
42. CD58 mutations are common in Hodgkin lymphoma cell lines and loss of CD58 expression in tumor cells occurs in Hodgkin lymphoma patients who relapse.
Abdul Razak FR; Diepstra A; Visser L; van den Berg A
Genes Immun; 2016 Sep; 17(6):363-6. PubMed ID: 27467287
[TBL] [Abstract][Full Text] [Related]
43. The genomic landscape of two Burkitt lymphoma cases and derived cell lines: comparison between primary and relapse samples.
Wever CM; Geoffrion D; Grande BM; Yu S; Alcaide M; Lemaire M; Riazalhosseini Y; Hébert J; Gavino C; Vinh DC; Petrogiannis-Haliotis T; Dmitrienko S; Mann KK; Morin RD; Johnson NA
Leuk Lymphoma; 2018 Sep; 59(9):2159-2174. PubMed ID: 29295643
[TBL] [Abstract][Full Text] [Related]
44. Comprehensive Genomic Profiling of Advanced Esophageal Squamous Cell Carcinomas and Esophageal Adenocarcinomas Reveals Similarities and Differences.
Wang K; Johnson A; Ali SM; Klempner SJ; Bekaii-Saab T; Vacirca JL; Khaira D; Yelensky R; Chmielecki J; Elvin JA; Lipson D; Miller VA; Stephens PJ; Ross JS
Oncologist; 2015 Oct; 20(10):1132-9. PubMed ID: 26336083
[TBL] [Abstract][Full Text] [Related]
45. Intrahepatic Cholangiocarcinoma: Genomic Heterogeneity Between Eastern and Western Patients.
Cao J; Hu J; Liu S; Meric-Bernstam F; Abdel-Wahab R; Xu J; Li Q; Yan M; Feng Y; Lin J; Zhao S; Wang J; Kwong LN; Hu J; Carapeto F; Borad MJ; Wang K; Javle M; Zhao H
JCO Precis Oncol; 2020; 4():. PubMed ID: 32923885
[TBL] [Abstract][Full Text] [Related]
46. Recurrent somatic mutations of PTPN1 in primary mediastinal B cell lymphoma and Hodgkin lymphoma.
Gunawardana J; Chan FC; Telenius A; Woolcock B; Kridel R; Tan KL; Ben-Neriah S; Mottok A; Lim RS; Boyle M; Rogic S; Rimsza LM; Guiter C; Leroy K; Gaulard P; Haioun C; Marra MA; Savage KJ; Connors JM; Shah SP; Gascoyne RD; Steidl C
Nat Genet; 2014 Apr; 46(4):329-35. PubMed ID: 24531327
[TBL] [Abstract][Full Text] [Related]
47. Tumor Mutation Burden and Efficacy of EGFR-Tyrosine Kinase Inhibitors in Patients with
Offin M; Rizvi H; Tenet M; Ni A; Sanchez-Vega F; Li BT; Drilon A; Kris MG; Rudin CM; Schultz N; Arcila ME; Ladanyi M; Riely GJ; Yu H; Hellmann MD
Clin Cancer Res; 2019 Feb; 25(3):1063-1069. PubMed ID: 30045933
[TBL] [Abstract][Full Text] [Related]
48. Comprehensive Genomic Profiling of Central Giant Cell Lesions Identifies Clinically Relevant Genomic Alterations.
Bezak B; Lehrke H; Elvin J; Gay L; Schembri-Wismayer D; Viozzi C
J Oral Maxillofac Surg; 2017 May; 75(5):955-961. PubMed ID: 27883876
[TBL] [Abstract][Full Text] [Related]
49. Nonamplification ERBB2 genomic alterations in 5605 cases of recurrent and metastatic breast cancer: An emerging opportunity for anti-HER2 targeted therapies.
Ross JS; Gay LM; Wang K; Ali SM; Chumsri S; Elvin JA; Bose R; Vergilio JA; Suh J; Yelensky R; Lipson D; Chmielecki J; Waintraub S; Leyland-Jones B; Miller VA; Stephens PJ
Cancer; 2016 Sep; 122(17):2654-62. PubMed ID: 27284958
[TBL] [Abstract][Full Text] [Related]
50. Integrated DNA/RNA targeted genomic profiling of diffuse large B-cell lymphoma using a clinical assay.
Intlekofer AM; Joffe E; Batlevi CL; Hilden P; He J; Seshan VE; Zelenetz AD; Palomba ML; Moskowitz CH; Portlock C; Straus DJ; Noy A; Horwitz SM; Gerecitano JF; Moskowitz A; Hamlin P; Matasar MJ; Kumar A; van den Brink MR; Knapp KM; Pichardo JD; Nahas MK; Trabucco SE; Mughal T; Copeland AR; Papaemmanuil E; Moarii M; Levine RL; Dogan A; Miller VA; Younes A
Blood Cancer J; 2018 Jun; 8(6):60. PubMed ID: 29895903
[TBL] [Abstract][Full Text] [Related]
51. Targeted DNA and RNA Sequencing of Paired Urothelial and Squamous Bladder Cancers Reveals Discordant Genomic and Transcriptomic Events and Unique Therapeutic Implications.
Hovelson DH; Udager AM; McDaniel AS; Grivas P; Palmbos P; Tamura S; Lazo de la Vega L; Palapattu G; Veeneman B; El-Sawy L; Sadis SE; Morgan TM; Montgomery JS; Weizer AZ; Day KC; Neamati N; Liebert M; Keller ET; Day ML; Mehra R; Tomlins SA
Eur Urol; 2018 Dec; 74(6):741-753. PubMed ID: 30033047
[TBL] [Abstract][Full Text] [Related]
52. In-depth cell-free DNA sequencing reveals genomic landscape of Hodgkin's lymphoma and facilitates ultrasensitive residual disease detection.
Sobesky S; Mammadova L; Cirillo M; Drees EEE; Mattlener J; Dörr H; Altmüller J; Shi Z; Bröckelmann PJ; Weiss J; Kreissl S; Sasse S; Ullrich RT; Reinke S; Klapper W; Gerhard-Hartmann E; Rosenwald A; Roemer MGM; Nürnberg P; Hagenbeek A; Zijlstra JM; Pegtel DM; Engert A; Borchmann P; von Tresckow B; Borchmann S
Med; 2021 Oct; 2(10):1171-1193.e11. PubMed ID: 35590205
[TBL] [Abstract][Full Text] [Related]
53. Somatic mutations of cell-free circulating DNA detected by targeted next-generation sequencing and digital droplet PCR in classical Hodgkin lymphoma.
Bessi L; Viailly PJ; Bohers E; Ruminy P; Maingonnat C; Bertrand P; Vasseur N; Beaussire L; Cornic M; Etancelin P; Camus V; Picquenot JM; Tilly H; Stamatoullas A; Jardin F
Leuk Lymphoma; 2019 Feb; 60(2):498-502. PubMed ID: 30068243
[No Abstract] [Full Text] [Related]
54. Detection of genomic imbalances in microdissected Hodgkin and Reed-Sternberg cells of classical Hodgkin's lymphoma by array-based comparative genomic hybridization.
Hartmann S; Martin-Subero JI; Gesk S; Hüsken J; Giefing M; Nagel I; Riemke J; Chott A; Klapper W; Parrens M; Merlio JP; Küppers R; Bräuninger A; Siebert R; Hansmann ML
Haematologica; 2008 Sep; 93(9):1318-26. PubMed ID: 18641027
[TBL] [Abstract][Full Text] [Related]
55. Subclonal evolution of a classical Hodgkin lymphoma from a germinal center B-cell-derived mantle cell lymphoma.
Schneider S; Crescenzi B; Schneider M; Ascani S; Hartmann S; Hansmann ML; Falini B; Mecucci C; Tiacci E; Küppers R
Int J Cancer; 2014 Feb; 134(4):832-43. PubMed ID: 23929122
[TBL] [Abstract][Full Text] [Related]
56. Highly recurrent mutations of SGK1, DUSP2 and JUNB in nodular lymphocyte predominant Hodgkin lymphoma.
Hartmann S; Schuhmacher B; Rausch T; Fuller L; Döring C; Weniger M; Lollies A; Weiser C; Thurner L; Rengstl B; Brunnberg U; Vornanen M; Pfreundschuh M; Benes V; Küppers R; Newrzela S; Hansmann ML
Leukemia; 2016 Apr; 30(4):844-53. PubMed ID: 26658840
[TBL] [Abstract][Full Text] [Related]
57. Targeted next-generation sequencing in chronic lymphocytic leukemia: a high-throughput yet tailored approach will facilitate implementation in a clinical setting.
Sutton LA; Ljungström V; Mansouri L; Young E; Cortese D; Navrkalova V; Malcikova J; Muggen AF; Trbusek M; Panagiotidis P; Davi F; Belessi C; Langerak AW; Ghia P; Pospisilova S; Stamatopoulos K; Rosenquist R
Haematologica; 2015 Mar; 100(3):370-6. PubMed ID: 25480502
[TBL] [Abstract][Full Text] [Related]
58. Comprehensive Genomic Profiling Reveals Diverse but Actionable Molecular Portfolios across Hematologic Malignancies: Implications for Next Generation Clinical Trials.
Galanina N; Bejar R; Choi M; Goodman A; Wieduwilt M; Mulroney C; Kim L; Yeerna H; Tamayo P; Vergilio JA; Mughal TI; Miller V; Jamieson C; Kurzrock R
Cancers (Basel); 2018 Dec; 11(1):. PubMed ID: 30583461
[No Abstract] [Full Text] [Related]
59. Alterations of CHEK2 forkhead-associated domain increase the risk of Hodgkin lymphoma.
Havranek O; Spacek M; Hubacek P; Mocikova H; Markova J; Trneny M; Kleibl Z
Neoplasma; 2011; 58(5):392-5. PubMed ID: 21744992
[TBL] [Abstract][Full Text] [Related]
60. [Preliminary analysis of mutations in exon 5 of IkappaBalpha gene in Hodgkin lymphoma].
Liu XJ; Yang WT; Zhou XY; Yan Q; Shi DR
Zhonghua Bing Li Xue Za Zhi; 2005 Jun; 34(6):341-4. PubMed ID: 16185501
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
